Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bristol-Myers releases mixed Opdivo lung cancer results

Bristol-Myers Squibb Co. released mixed results from clinical trials testing the survival benefit of the immunotherapy Opdivo in combination with either chemotherapy or the company’s other immuno-oncology drug Yervoy as an initial treatment for advanced lung cancer.

Read More »

Amgen drug shows high response rate in small lung and colon cancer trial

An experimental Amgen Inc. drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, sending the U.S. biotechnology company’s share up nearly 6 percent.

Read More »

Merck’s Keytruda sets new five-year survival standard for advanced lung cancer

Nearly a quarter of patients who received Merck & Co.’s immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting.

Read More »

Bristol-Myers pulls U.S. application for combo lung cancer treatment

Bristol-Myers Squibb withdrew the U.S. approval application for a combo of the cancer immunotherapy drugs Opdivo and Yervoy.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom